There is disclosed compositions and methods relating to or derived from anti-JAG1 antibodies. More specifically, there is disclosed fully human antibodies that bind JAG1, JAG1-binding fragments and derivatives of such antibodies, and JAG1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having JAG1 related disorders or conditions. There is also disclosed a method for treating JAG1-expressing tumors, including hepatocellular carcinomas and squamous carcinomas, and non-oncology diseases selected from the group consisting of rheumatoid arthritis, experimental lung injury, atherosclerosis, chronic liver disease induced by hepatitis C virus, ischemic myocardial injury and heart failure.L'invention concerne des compositions et des procédés se rapportant aux anticorps anti-JAG1 ou dérivés de ceux-ci. Plus spécifiquement, l'invention concerne des anticorps entièrement humains se liant à JAG1, des fragments se liant à JAG1 et des dérivés de ces anticorps, et des polypeptides se liant à JAG1 comprenant lesdits fragments. L'invention concerne encore des acides nucléiques codant ces anticorps, fragments d'anticorps, dérivés et polypeptides, des cellules contenant ces polynucléotides, des procédés de préparation de ces anticorps, fragments d'anticorps, dérivés et polypeptides, et des méthodes d'utilisation de ces anticorps, fragments d'anticorps et dérivés et polypeptide, comprenant des méthodes de traitement ou de diagnostic de maladies ou de troubles associés à JAG1 chez des sujets. L'invention concerne également une méthode de traitement de tumeurs exprimant JAG1, notamment les carcinom
